Canadian medical cannabis clinic Santé Cannabis has started recruitment for a new study assessing the effectiveness of various cannabis treatment plans.
Citing the ‘many unanswered questions’ surrounding the therapeutic potential of cannabis, which has been legal for medical uses in Canada since 2001, the study will examine the patient outcomes of 3000 medical cannabis patients.
Specificially, it will explore the efficacy of emerging cannabis treatments and product formats, including capsules, tablets and sublingual options, alongside newer cannabinoids like CBN and CBD.
Dr. Michael Dworkind, Medical Director and Co-founder of Santé Cannabis, said: “Despite nearly 25 years of legalized medical cannabis in Canada, there are still many unanswered questions about its therapeutic potential for conditions such as chronic pain, epilepsy, spasticity, sleep disorders, anxiety, and depression. This study is a critical step in addressing patients’ needs in the evolving cannabis landscape.”
Major cannabis brands, including Tilray, Aroura Cannabis and Singaporian CBD company Vectura Fertin Pharma are helping fund the study, but Santé is understood to be searching for additional partners to work with on the initiative.
Canada is currently one of the largest medical cannabis markets on the planet, and as of March 2024 had more than 180,000 registered medical cannabis patients with federally assisted licensed sellers.
Santé has supported over 20,000 patients since its inception in 2014, and was Canada’s first accredited cannabis Contract Research Organization (CRO), having conducted clinical trials and observational studies under four Cannabis Research Licenses.
The post Canadian Medical Cannabis Clinic Launches 3000-Participant Study into Emerging Cannabis Treatments appeared first on Business of Cannabis.
Continue reading...
